Passage BIO, Inc. files 10-K

Passage Bio, a clinical-stage genetic medicines company, reported a net loss of $45.5 million for the year ended December 31, 2025, a decrease from the prior year's loss of $64.8 million. The company continues to advance its lead product candidate, PBFT02, for neurodegenerative diseases and expects its current cash reserves to fund operations through the first quarter of 2027.